Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY-NC-ND 4.0International Forum of Allergy & Rhinology

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

  • Li Hu1
  • Houyong Li1
  • Xicai Sun1
  • Quan Liu1
  • Yu Xu2
  • Jiangang Fan3
  • Andrew Foster4
  • Claudia Chen5
  • Yun Chon6
  • Dehui Wang1
6 affiliations
  1. 1Eye & ENT Hospital of Fudan University Shanghai China
  2. 2Renmin Hospital of Wuhan University Wuhan Hubei China
  3. 3Sichuan Provincial People's Hospital Chengdu Sichuan China
  4. 4Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca Gaithersburg Maryland USA
  5. 5BioPharmaceuticals R&D, Respiratory & Immunology Biometrics & Statistical Innovation, AstraZeneca Gaithersburg Maryland USA
  6. 6Global Development, Amgen Thousand Oaks California USA
Read full textDOICite

Abstract

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese patients with CRSwNP.

Methods: Adult patients with severe CRSwNP were randomized 1:1 to tezepelumab (210 mg) or placebo for 52 weeks. Co‐primary endpoints were changes from baseline at Week 52 (W52) in total nasal‐polyp score and bi‐weekly mean nasal‐congestion score. Key secondary endpoints included changes from baseline in Nasal Polyposis Symptom Diary (NPSD) loss‐of‐smell score, 22‐item Sinonasal Outcome Test (SNOT‐22) total score, Lund–Mackay score, NPSD total symptom score, and time to first nasal‐polyp surgery decision and/or systemic glucocorticoid use.

Results: Twenty‐nine patients received tezepelumab, and 34 received placebo. At W52, tezepelumab achieved numerically greater improvements in total nasal‐polyp score (least‐squares mean difference vs. placebo [95% CI]: −2.03 [−2.88, −1.19]) and bi‐weekly mean nasal‐congestion score (−0.72 [−1.23, −0.21]). Compared with placebo, tezepelumab also improved NPSD loss‐of‐smell score (−0.44 [−0.82, −0.06]), SNOT‐22 total score (−16.34 [−29.80, −2.88]), Lund–Mackay score (−5.30 [−7.23, −3.38]), and NPSD total symptom score (−3.76 [−6.89, −0.63]). No tezepelumab‐treated patients required nasal‐polyp surgery or systemic glucocorticoids.

Conclusion: Consistent with the overall population, tezepelumab reduced nasal‐polyp size and improved loss‐of‐smell and other sinonasal symptoms in Chinese patients with CRSwNP, with a favorable safety profile. No surgery or systemic glucocorticoids were required. These benefits were observed despite relatively lower baseline eosinophil counts in these patients. Further investigation is warranted to assess the generalizability to the broader Chinese population with CRSwNP.

Related

  1. Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes ― Prespecified Subgroup Analysis of the STOPDAPT-3 Trial ―
    Kenji Kanenawa, Ko Yamamoto, Takenori Domei +23
    Circulation JournalPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE
  2. Effects of minocycline on health-related quality of life in patients with acute ischaemic stroke in China: a prespecified secondary analysis of the EMPHASIS trial
    Qianqian Yang, Ying Li, Luyan Wang +16
    EClinicalMedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Increased expression of hPGDS‑PGD2 in patients with eosinophilic chronic rhinosinusitis with nasal polyps
    Jing Li, Xiwen Zhu, Ling Cai
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Ocular Surface Findings in Patients with Surgery-Indicated Chronic Rhinosinusitis with Nasal Polyps: A Retrospective Study
    Efnan Abdioğlu Fazlı, Büşra Köse, Ömer K. Kurutaş +1
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Interleukin-17 in the Nasal Polyps of Patients with Chronic Rhinosinusitis Compared to Healthy Controls: A Systematic Review
    Paraskevi Karamitsou, Alexandros Poutoglidis, Kalliopi Domvri +4
    International Archives of OtorhinolaryngologyPeer-reviewedCC BYFull textGeneral medicineDOAJ

Cite

BibTeXRIS
BibTeX
@article{hu2026tezepelumab,
  title = {{Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial}},
  author = {Li Hu and Houyong Li and Xicai Sun and Quan Liu and Yu Xu and Jiangang Fan and Andrew Foster and Claudia Chen and Yun Chon and Dehui Wang},
  journal = {International Forum of Allergy \& Rhinology},
  year = {2026},
  month = jul,
  doi = {10.1002/alr.70208},
  url = {https://doi.org/10.1002/alr.70208},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial
AU  - Li Hu
AU  - Houyong Li
AU  - Xicai Sun
AU  - Quan Liu
AU  - Yu Xu
AU  - Jiangang Fan
AU  - Andrew Foster
AU  - Claudia Chen
AU  - Yun Chon
AU  - Dehui Wang
PY  - 2026
DA  - 2026/07/29
JO  - International Forum of Allergy & Rhinology
DO  - 10.1002/alr.70208
UR  - https://doi.org/10.1002/alr.70208
AB  - Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese patients with CRSwNP.  Methods: Adult patients with severe CRSwNP were randomized 1:1 to tezepelumab (210 mg) or placebo for 52 weeks. Co‐primary endpoints were changes from baseline at Week 52 (W52) in total nasal‐polyp score and bi‐weekly mean nasal‐congestion score. Key secondary endpoints included changes from baseline in Nasal Polyposis Symptom Diary (NPSD) loss‐of‐smell score, 22‐item Sinonasal Outcome Test (SNOT‐22) total score, Lund–Mackay score, NPSD total symptom score, and time to first nasal‐polyp surgery decision and/or systemic glucocorticoid use.  Results: Twenty‐nine patients received tezepelumab, and 34 received placebo. At W52, tezepelumab achieved numerically greater improvements in total nasal‐polyp score (least‐squares mean difference vs. placebo [95% CI]: −2.03 [−2.88, −1.19]) and bi‐weekly mean nasal‐congestion score (−0.72 [−1.23, −0.21]). Compared with placebo, tezepelumab also improved NPSD loss‐of‐smell score (−0.44 [−0.82, −0.06]), SNOT‐22 total score (−16.34 [−29.80, −2.88]), Lund–Mackay score (−5.30 [−7.23, −3.38]), and NPSD total symptom score (−3.76 [−6.89, −0.63]). No tezepelumab‐treated patients required nasal‐polyp surgery or systemic glucocorticoids.  Conclusion: Consistent with the overall population, tezepelumab reduced nasal‐polyp size and improved loss‐of‐smell and other sinonasal symptoms in Chinese patients with CRSwNP, with a favorable safety profile. No surgery or systemic glucocorticoids were required. These benefits were observed despite relatively lower baseline eosinophil counts in these patients. Further investigation is warranted to assess the generalizability to the broader Chinese population with CRSwNP.
SN  - 2042-6976
SN  - 2042-6984
ER  -